| Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts, ... New England Journal of Medicine 352 (25), 2589-2597, 2005 | 2314 | 2005 |
| Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review JJ Caro, M Salas, A Ward, G Goss Cancer 91 (12), 2214-2221, 2001 | 1339 | 2001 |
| Probability of cancer in pulmonary nodules detected on first screening CT A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ... New England journal of medicine 369 (10), 910-919, 2013 | 1297 | 2013 |
| Apixaban to prevent venous thromboembolism in patients with cancer M Carrier, K Abou-Nassar, R Mallick, V Tagalakis, S Shivakumar, ... New England Journal of Medicine 380 (8), 711-719, 2019 | 794 | 2019 |
| Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study G Goss, CM Tsai, FA Shepherd, L Bazhenova, JS Lee, GC Chang, ... The lancet oncology 17 (12), 1643-1652, 2016 | 668 | 2016 |
| Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non–small-cell lung cancer C Butts, N Murray, A Maksymiuk, G Goss, E Marshall, D Soulières, ... Journal of Clinical Oncology 23 (27), 6674-6681, 2005 | 547 | 2005 |
| Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial JC Soria, E Felip, M Cobo, S Lu, K Syrigos, KH Lee, E Göker, ... The lancet oncology 16 (8), 897-907, 2015 | 499 | 2015 |
| Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non–small-cell lung cancer: updated survival analysis … CA Butts, K Ding, L Seymour, P Twumasi-Ankrah, B Graham, D Gandara, ... Journal of clinical oncology 28 (1), 29, 2010 | 480 | 2010 |
| Gefitinib versus placebo in completely resected non–small-cell lung cancer: results of the NCIC CTG BR19 study GD Goss, C O'Callaghan, I Lorimer, MS Tsao, GA Masters, J Jett, ... Journal of clinical oncology 31 (27), 3320, 2013 | 382 | 2013 |
| Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials TR Asmis, K Ding, L Seymour, FA Shepherd, NB Leighl, TL Winton, ... Journal of Clinical Oncology 26 (1), 54-59, 2008 | 379 | 2008 |
| A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ... British journal of cancer 95 (9), 1148-1154, 2006 | 379 | 2006 |
| Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non–small-cell lung cancer RB Natale, S Thongprasert, FA Greco, M Thomas, CM Tsai, ... Journal of Clinical Oncology 29 (8), 1059-1066, 2011 | 308 | 2011 |
| Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer S Jenkins, JCH Yang, SS Ramalingam, K Yu, S Patel, S Weston, R Hodge, ... Journal of Thoracic Oncology 12 (7), 1061-1070, 2017 | 282 | 2017 |
| Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non–small-cell lung cancer: NCIC Clinical Trials Group BR24 … GD Goss, A Arnold, FA Shepherd, M Dediu, TE Ciuleanu, D Fenton, ... Journal of clinical oncology 28 (1), 49-55, 2010 | 255 | 2010 |
| The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials A Lazo‐Langner, GD Goss, JN Spaans, MA Rodger Journal of Thrombosis and Haemostasis 5 (4), 729-737, 2007 | 246 | 2007 |
| Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy … AM Arnold, L Seymour, M Smylie, K Ding, Y Ung, B Findlay, CW Lee, ... Journal of Clinical Oncology 25 (27), 4278-4284, 2007 | 231 | 2007 |
| Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label … C Butts, A Maksymiuk, G Goss, D Soulieres, E Marshall, Y Cormier, ... Journal of cancer research and clinical oncology 137, 1337-1342, 2011 | 222 | 2011 |
| CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials G Goss, CM Tsai, FA Shepherd, MJ Ahn, L Bazhenova, L Crinò, ... Annals of Oncology 29 (3), 687-693, 2018 | 211 | 2018 |
| Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study MC Tammemagi, H Schmidt, S Martel, A McWilliams, JR Goffin, ... The lancet oncology 18 (11), 1523-1531, 2017 | 205 | 2017 |
| Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? PA Bunn Jr, JD Minna, A Augustyn, AF Gazdar, Y Ouadah, MA Krasnow, ... Journal of Thoracic Oncology 11 (4), 453-474, 2016 | 200 | 2016 |
Ming TsaoUniversity of Toronto, University Health Network, Princess Margaret Cancer CentreVerified email at uhn.ca
